Could a gut pill ease long COVID? new trial tests larazotide

NCT ID NCT05747534

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2a study tests whether larazotide, a drug that tightens the gut lining, can reduce long COVID symptoms in people aged 7 to 50. Participants take the drug or a placebo four times daily for 21 days. The goal is to see if it safely improves symptoms like fatigue, brain fog, and breathing trouble.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Larazotide (AT1001), a drug that tightens the gut lining to reduce inflammation
What this could lead to: If it works, this could point toward a treatment for long COVID by addressing gut-related inflammation.
What could go wrong: This is an early Phase 2a trial with only 150 participants, so results may not apply to everyone. The drug is taken four times daily for 21 days, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID LONG COVID-19 POST ACUTE SEQUELAE OF COVID-19 POST-ACUTE COVID-19 SYNDROME

Could a gut pill ease long COVID? new trial tests larazotide

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions